Back to search
Chemotherapy-Related Cognitive Impairment
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Chemotherapy-Related Cognitive Impairment trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Chemotherapy-Related Cognitive Impairment trials you may qualify forChemotherapy is toxic and challenges everyone differently. Most chemotherapy side-effects are known and well documented. However, the phenomenon of "chemo fog"…
This research study evaluates the effect of chemotherapy on cognition (thinking) and the brain in people with breast cancer.
Chemotherapy-induced cognitive impairment (CICI), also known as "chemobrain," is a range of neurocognitive deficits experienced during and after cancer chemothe…
This prospective, non-randomized diagnostic interventional study evaluates cognitive impairment in patients with diffuse large B-cell lymphoma (DLBCL) treated a…
Breast cancer is one of the most common cancers in metropolitan France, with over 60,000 new cases in 2023. Mostly a female cancer, it can affect a young popula…
Cancer-related cognitive impairment (CRCI), also known as "chemobrain," is the cognitive decline that negatively impacts the majority of cancer patients undergo…
Breast cancer is one of the most common cancer types worldwide and accounts for approximately 31% of all cancers in women. The global incidence of breast cancer…
This is a phase I, dose-escalation and phase II dose-expansion clinical trial determining the maximum tolerated dose (MTD) and safety and tolerability of adding…